Literature DB >> 15067631

Reversibility of cirrhosis in chronic hepatitis B.

Reza Malekzadeh1, Mehdi Mohamadnejad, Nasser Rakhshani, Siavosh Nasseri-Moghaddam, Shahin Merat, Seyed Mohamad Tavangar, Amir Ali Sohrabpour.   

Abstract

BACKGROUND & AIMS: Hepatic fibrosis and cirrhosis are the consequences of many types of chronic liver disease, and, at its final stage when liver nodule and scarring develop, they are generally considered to be irreversible.
METHODS: Here we describe 3 patients with chronic hepatitis B with clinical, biochemical, and histologic evidence of cirrhosis. They underwent treatment with interferon-alpha or lamivudine and had follow-up liver biopsy while in clinical, biochemical, and virologic remission. Biopsy specimens were randomly coded in unpaired manner according to patient, and they were read independently by 2 pathologists using the modified hepatitis activity index (with a maximum stage of 6). The mean interval between biopsies was 5.5 years.
RESULTS: The mean ALT level decreased from 113.7 to 28.3 U/L. The mean bilirubin level decreased from 2.4 to 0.9 mg/dL, and the mean prothrombin time decreased from 16.3 to 12.3 seconds. The mean Child-Pugh score decreased from 8 to 5. The mean fibrosis score decreased from 5.8 to 0.5 (P = 0.004), and the mean grading score decreased from 10.8 to 3.2 (P = 0.017).
CONCLUSIONS: Cirrhosis due to chronic hepatitis B might be reversible in some patients who respond to antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15067631     DOI: 10.1016/s1542-3565(04)00066-7

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  10 in total

Review 1.  When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response.

Authors:  Wonseok Kang; Jun Yong Park
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

2.  Therapeutic effect of interleukin-10 on CCl4-induced hepatic fibrosis in rats.

Authors:  Yue-Hong Huang; Mei-Na Shi; Wei-Da Zheng; Li-Juan Zhang; Zhi-Xin Chen; Xiao-Zhong Wang
Journal:  World J Gastroenterol       Date:  2006-03-07       Impact factor: 5.742

Review 3.  Evaluation and management of patients with refractory ascites.

Authors:  Bahaa Eldeen Senousy; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

4.  Fibroscan for assessing liver fibrosis: An acceptable alternative for liver biopsy: Fibroscan: an acceptable alternative for liver biopsy.

Authors:  Reza Malekzadeh; Hossein Poustchi
Journal:  Hepat Mon       Date:  2011-03       Impact factor: 0.660

5.  Evaluation of Liver Fibrosis Using Texture Analysis on Combined-Contrast-Enhanced Magnetic Resonance Images at 3.0T.

Authors:  Takeshi Yokoo; Tanya Wolfson; Keiko Iwaisako; Michael R Peterson; Haresh Mani; Zachary Goodman; Christopher Changchien; Michael S Middleton; Anthony C Gamst; Sameer M Mazhar; Yuko Kono; Samuel B Ho; Claude B Sirlin
Journal:  Biomed Res Int       Date:  2015-09-01       Impact factor: 3.411

6.  Antiviral therapy leads to histological improvement of HBeAg-negative chronic hepatitis B patients.

Authors:  Nikolaos Papachrysos; Prodromos Hytiroglou; Lavrentios Papalavrentios; Emmanouil Sinakos; Ioannis Kouvelis; Evangelos Akriviadis
Journal:  Ann Gastroenterol       Date:  2015 Jul-Sep

Review 7.  Improving Quality of Care in Patients with Liver Cirrhosis.

Authors:  Mehdi Saberifiroozi
Journal:  Middle East J Dig Dis       Date:  2017-10

8.  Proteomic study of advanced cirrhosis based on HCV to reveal potential biomarkers.

Authors:  Akram Safaei; Afsaneh Arefi Oskouie; Seyed Reza Mohebbi; Zahra Razaghi; Naser Nejadi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2020

9.  Etiology and complications of liver cirrhosis in children:report of a single center from southern iran.

Authors:  Seyed Mohsen Dehghani; Mohammad Hadi Imanieh; Mahmood Haghighat; Abdorrasoul Malekpour; Zeinab Falizkar
Journal:  Middle East J Dig Dis       Date:  2013-01

10.  Cell-based regenerative therapy as an alternative to liver transplantation for end-stage liver disease: experience from iran.

Authors:  R Malekzadeh; M Mohamadnejad; K Alimoghaddam; M Bagheri; H Baharvand; A Ghavamzadeh
Journal:  Int J Organ Transplant Med       Date:  2010-02-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.